

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ

雑誌

発表者氏名	論文タイトル名	発表誌名	巻・号	ページ	出版年
Oze T;Hiramatsu N;Mita E;Akuta N; <u>Sakamoto N</u> ;Itoh Y;Izumi N;Nomura H;Hayashi N;Takehara T	A multi-center survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.	Hepato Res			2013 in press
Kiyohashi K;Kakinuma S;Kamiya A; <u>Sakamoto N</u> ;Nitta S;Yamanaka H;Yoshino K;Fujiki J;Murakawa M;Kusano-Kitazume A;Shimizu H;Okamoto R;Azuma S;Nakagawa M;Asahina Y;Tanimizu N;Kikuchi A;Nakauchi H;Watanabe M	Wnt5a Signaling Mediates Biliary Differentiation of Fetal Hepatic Stem/Progenitor Cells.	Hepatology			2013 in press
Huang JT;Tseng CP;Liao MH;Lu SC;Yeh WZ; <u>Sakamoto N</u> ;Chen CM;Cheng JC	Hepatitis C virus replication is modulated by the interaction of non-structural protein NS5B and fatty acid synthase.	J Virol			2013 in press

Kurosaki M;Tanaka Y;Nishida N; <u>Sakamoto N</u> ;Enomoto N;Matsuura K;Asahina Y;Nakagawa M;Watanabe M;Sakamoto M;Maekawa S;Tokunaga K;Mizokami M;Izumi N	A model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.	J Med Virol	89	449-458	2013
Nitta S; <u>Sakamoto N</u> ;Nakagawa M;Kakinuma S;Mishima K;Kusano-Kitazume A;Kiyohashi K;Murakawa M;Nishimura-Sakurai Y;Azuma S;Tasaka-Fujita M;Asahina Y;Yoneyama M;Fujita T;Watanabe M	Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity	Hepatology	57 (1)	46-58	2013
Kohjima M;Enjoji M;Yoshimoto T;Yada R;Fujino T;Aoyagi Y;Fukushima N;Fukuizumi K;Harada N;Yada M;Kato M;Kotoh K;Nakashima M; <u>Sakamoto N</u> ;Tanaka Y;Nakamuta M	Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C	J Med Virol	85 (2)	250-60	2013

Nakagawa M; <u>Sakamoto N</u> ;Watanabe T;Nishimura-Sakurai Y;Onozuka I;Azuma S;Kakinuma S;Nitta S;Kiyohashi K;Kusano-Kitazume A;Murakawa M;Yoshino K;Itsui Y;Tanaka Y;Mizokami M;Watanabe M;Group OLCS	Association of ITPA gene variant and serum ribavirin concentration with blood cells decline in pegylated interferon-alfa plus ribavirin therapy for chronic hepatitis C.	Hepato Int			2012 EPub ahead of print
Yamashita A;Salam KA;Furuta A;Matsuda Y;Fujita O;Tani H;Fujita Y;Fujimoto Y;Ikeda M;Kato N; <u>Sakamoto N</u> ;Maekawa S;Enomoto N;Nakakoshi M;Tsubuki M;Sekiguchi Y;Tsuneda S;Akimitsu N;Noda N;Tanaka J;Moriishi K	Inhibition of Hepatitis C Virus Replication and Viral Helicase by Ethyl Acetate Extract of the Marine Feather Star <i>Alloeocomatella polycladia</i>	Marine Drugs	10 (4)	744-761	2012
Sakurai F;Furukawa N;Higuchi M;Okamoto S;Ono K;Yoshida T;Kondoh M;Yagi K; <u>Sakamoto N</u> ;Katayama K;Mizuguchi H	Suppression of hepatitis C virus replicon by adenovirus vector-mediated expression of tough decoy RNA against miR-122a	Virus Research	165 (2)	214-218	2012

Saito H;Ito K;Sugiyama M;Matsui T;Aoki Y;Imamura M;Murata K;Masaki N;Nomura H;Adachi H;Hige S;Enomoto N; <u>Sakamoto N</u> ;Kurosaki M;Mizokami M;Watanabe S	Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients	Hepatol Res	42 (10)	958-965	2012
Nichols DB;Fournet G;Gurukumar KR;Basu A;Lee JC; <u>Sakamoto N</u> ;Kozielski F;Musmuca I;Joseph B;Ragno R;Kaushik-Basu N	Inhibition of hepatitis C virus NS5B polymerase by S-trityl-L-cysteine derivatives	Eur J Med Chem	49	191-9	2012
Li YJ;Wu HH;Weng CH;Chen YC;Hung CC;Yang CW;Wang RY; <u>Sakamoto N</u> ;Tian YC	Cyclophilin A and Nuclear Factor of Activated T Cells Are Essential in Cyclosporine-Mediated Suppression of Polyomavirus BK Replication	Am J Transplant	12 (9)	2348-62	2012
Kusano-Kitazume A; <u>Sakamoto N</u> ;Okuno Y;Sekine-Osajima Y;Nakagawa M;Kakinuma S;Kiyohashi K;Nitta S;Murakawa M;Azuma S;Nishimura-Sakurai Y;Hagiwara M;Watanabe M	Identification of novel N-(morpholine-4-carboxyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication	Antimicrob Agents Chemother	56 (3)	1315-23	2012
Kurosaki M;Hiramatsu N;Sakamoto M;Suzuki Y;Iwasaki M;Tamori A;Matsuura K;Kakinuma S;Sugauchi F; <u>Sakamoto N</u> ;Nakagawa M;Yatsuhashi H;Izumi N	Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis	Antivir Ther	17 (1)	35-43	2012

Kurosaki M;Hiramatsu N;Sakamoto M;Suzuki Y;Iwasaki M;Tamori A;Matsuura K;Kakinuma S;Sugauchi F;Sakamoto N;Nakagawa M;Izumi N	Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C	J Hepatol	56 (3)	602-8	2012
Kobayashi T;Hige S;Terashita K;Nakai M;Horimoto H;Sho T;Nakanishi M;Ogawa K;Chuma M;Sakamoto N;Asaka M	Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C	J Gastroenterol	47 (11)	1228-37	2012
Fujimoto Y;Salam KA;Furuta A;Matsuda Y;Fujita O;Tani H;Ikeda M;Kato N;Sakamoto N;Maekawa S;Enomoto N;de Voogd NJ;Nakakoshi M;Tsubuki M;Sekiguchi Y;Tsuneda S;Akimitsu N;Noda N;Yamashita A;Tanaka J;Moriishi K	Inhibition of both protease and helicase activities of hepatitis C virus NS3 by an ethyl acetate extract of marine sponge Amphimedon sp	PLoS One	7 (11)	e48685	2012
Cheng JC;Yeh YJ;Tseng CP;Hsu SD;Chang YL;Sakamoto N;Huang HD	Let-7b is a novel regulator of hepatitis C virus replication	Cell Mol Life Sci	69 (15)	2621-33	2012

Asahina Y;Tsuchiya K;Muraoka M;Tanaka K;Suzuki Y;Tamaki N;Hoshioka Y;Yasui Y;Katoh T;Hosokawa T;Ueda K;Nakanishi H;Itakura J;Takahashi Y;Kurosaki M;Enomoto N;Nitta S;Sakamoto N;Izumi N	Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response	Hepatology	55 (1)	20-29	2012
---	--	------------	--------	-------	------

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Shi N, Hiraga N, <u>Imamura M</u> , Hayes CN, Zhang Y, Kosaka K, Okazaki A, Murakami E, Tsuge M, Abe H, Aikata H, Takahashi S, Ochi H, Tateno-Mukaidani C, Yoshizato K, Matsui H, Kanai A, Inaba T, McPhee F, Gao M, Chayama K	Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.	Gut			2013, in press

研究成果の刊行に関する一覧表レイアウト（参考）

書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ
------	---------	---------------	-------	------	-----	-----	-----

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Matsuda H, Ito Y, Suto H, Yamakawa A, Satomi S, Ohtani M Yamazaki Y, Kusaka Y, Shimabukuro Y, Kikuchi K, Keida Y, Azuma T, Nakamoto Y	Clinical relevance and sequence analysis of the Helicobacter pylori dupA region from two areas in Japan with different gastric cancer risks.	Immuno-Gastro enterology	1(2)	127-135	2012
Marukawa Y, Nakamoto Y, Kakinoki K, Tsuchiyama T, Iida N, Kagaya T, Sakai Y, Naito M, Mukaida N, Kaneko S	Membrane-bound form of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy in a model of hepatocellular carcinoma.	Cancer Gene Ther.	19(5)	312-319	2012
Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, Zeng SS, Kondo TH, Takatori H, Yamashita T, Mizukoshi E, Ikeda H, Zen Y, Takamura H, Wang XW, Kaneko S	Discrete nature of EpCAM(+) and CD90(+) cancer stem cells in human hepatocellular carcinoma.	Hepatology	(in press)		2012

研究成果の刊行に関する一覧表（堀田 博）

書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
El-Shamy A, Shoji I, El-Akel W, Bilasy SE, Deng L, El-Raziky M, Jiang DP, Esmat G, Hotta H.	NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon /ribavirin therapy in Egyptian patients.	J Clin Microbiol	50(12)	3886-92.	2012
Yano Y, Seo Y, Miki A, Saito M, Kato H, Hamano K, Oya M, Ouchi S, Fujisawa T, Yamada H, Yamashita Y, Tani S, Hirohata S, Yoon S, Kitajima N, Kitagaki K, Kawara A, Nakashima T, Yu H, Maeda T, Azuma T, El-Shamy A, Hotta H, Hayashi Y.	Mutations in non-structural 5A and rapid viral response to pegylated interferon- α -2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.	Int J Mol Med	30(5)	1048-52.	2012
Kim SR, El-Shamy A, Imoto S, Kim KI, Ide YH, Deng L, Shoji I, Tanaka Y, Hasegawa Y, Ota M, Hotta H.	Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.	J Gastroentero l	47(10)	1143-51.	2012

El-Shamy A, Shoji I, Kim SR, Ide Y, Imoto S, Deng L, Yoon S, Fujisawa T, Tani S, Yano Y, Seo Y, Azuma T, <u>Hotta H</u>	Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon /ribavirin therapy.	PLoS ONE	7(2)	e30513	2012
Matsui C, Shoji I, Kaneda S, Sianipar IR, Deng L, <u>Hotta H</u>	Hepatitis C virus infection suppresses GLUT2 gene expression via down-regulation of hepatocyte nuclear factor 1 α .	J Virol	86(23)	12903-11.	2012
Nakashima K, Takeuchi K, Chihara K, Horiguchi T, Sun X, Deng L, Shoji I, <u>Hotta H</u> , Sada K.	HCV NS5A protein containing potential ligands for both Src homology 2 and 3 domains enhances autophosphorylation of Src family kinase Fyn in B cells.	PLoS ONE	7(10)	e46634.	2012
Sasayama M, Shoji I, Adianti M, Jiang D-P, Deng L, Saito T, Watanabe H, Kawata S, Aoki C, <u>Hotta H</u>	A point mutation at ASN-534 that disrupts a conserved N-glycosylation motif of the E2 glycoprotein of hepatitis c virus markedly enhances the sensitivity to antibody neutralization.	J Med Virol	84(2)	229-234	2012
Shoji I, Deng L, <u>Hotta H</u>	Molecular mechanism of hepatitis C virus-induced glucose metabolic disorders.	Front Microbiol	2: A278	1-5	2012
El-Shamy A, Shindo M, Shoji I, Deng L, Okuno T, <u>Hotta H</u> .	Polymorphisms of the core, NS3 and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma.	Hepatology	In press		

Utsumi T, Yano Y, Lusida MI, Nasronudin, Amin M, Juniastuti, Soetjipto, <u>Hotta H</u> , <u>Hayashi Y</u> .	Detection of highly prevalent hepatitis B virus co-infection with HIV in Indonesia.	Hepatol Res	In press		
進藤 道子, El-Shamy Ahmed, 奥野 忠雄, <u>堀田 博</u> .	C型慢性肝炎時から 肝癌発生まで経過を 追えたC型肝炎ウイ ルスジェノタイプ1b のコア蛋白アミノ酸 多様性と肝癌発生と の関連性.	肝臓	53(9)	541-548.	2012
Shimizu YK, Hijikata M, Oshima M, Shimizu K, Alter HJ, Purcell RH, Yoshikura H, <u>Hotta H</u> .	Isolation of human monoclonal antibodies to the envelope E2 protein of hepatitis C virus and their characterization.	PLoS One	8(2)	e55874	2013

研究成果の刊行に関する一覧表

書籍

なし

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>Suzuki T.</u>	Morphogenesis of infectious hepatitis C virus particles	Front. Microbiol.	3	38	2012
Ando T., Imamura H., Suzuki R., Aizaki H., Watanabe T., Wakita T, and <u>Suzuki T.</u>	Visualization and measurement of ATP levels in living cells replicating hepatitis C virus genome RNA.	PLoS Pathog.	8	e10025 61	2012
Suzuki R., Saito K., Kato T., Shirakura M., Akazawa D., Ishii K., Aizaki H., Kanegae Y., Matsuura Y., Saito I., Wakita T., and <u>Suzuki T.</u>	Trans-complemented hepatitis C virus particles as a versatile tool for study of virus assembly and infection.	Virology	432	29-38	2012
Fukazawa H, <u>Suzuki T</u> , Wakita T, Murakami Y.	A cell-based, microplate colorimetric screen identifies 7,8-benzoflavone and green tea gallate catechins as inhibitors of the hepatitis C virus.	Biol Pharm Bull.	35	1320-1 327	2012
Saeed M, Gondeau C, Hmwe S, Yokokawa H, Date T, <u>Suzuki T</u> , Kato T, Maurel P, Wakita T, Shimakami T, Yi M, Lemon SM, <u>Suzuki T</u> , Wakita T, Kaneko S. T.	Replication of Hepatitis C Virus Genotype 3a in Cultured Cells.	Gastroente rology	144	56-58	2012
Murakami Y, Fukasawa M,	Selective estrogen receptor modulators	Microbes Infect.	15	45-55	2013

Kaneko Y, <u>Suzuki</u> <u>T</u> , Wakita T, Fukazawa H.	inhibit hepatitis C virus infection at multiple steps of the virus life cycle.				
--	---	--	--	--	--

研究成果の刊行に関する一覧表レイアウト（参考）

書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ
鈴木文孝	B型肝炎の抗ウイルス療法 ①ガイドライン【4】	熊田博光	インフォームド コンセントのた めの図説シリ ーズ	医薬ジャー ナル社	大阪	2012	28-31

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Koyabashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H.	Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment	Intervirology	55	417-425	2012
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H.	Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy	Intervirology	55	231-241	2012
Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Complicated Relationships of Amino Acid Substitution in Hepatitis C Virus Core Region and IL28B Genotype Influencing Hepatocarcinogenesis	Hepatology	56	2134-2141	2012

Hanada K, Nakai K, Tanaka H, <u>Suzuki F</u> , Kumada H. Ohno Y, Ozawa S, Ogawa H.	Effect of Nuclear Receptor Downregulation on Hepatic Expression of Cytochrome P450 and Transporters in Chronic Hepatitis C in Association with Fibrosis Development	Drug Metab. Pharmacokinet.	27	301-306	2012
<u>Suzuki F</u> , Arase Y, Suzuki Y, Akuta N, Sezaki H, Seko Y, Kawamura Y, Hosaka T, Kobayabashi M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan	J Gastroenterol	47	814-822	2012
<u>Suzuki F</u> , Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H.	Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b	J Clin Virol	54	352-354	2012
Ono A, <u>Suzuki F</u> , Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H.	Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients	J Hepatol	57	508-514	2012
Mori N, <u>Suzuki F</u> , Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection	J Gastroenterol	47	1022-1029	2012
Arase Y, Kawamura Y, Suzuki Y, <u>Suzuki F</u> , Akuta N, Matsumoto N, Seko Y, Sezaki H, Kobayashi M, Hosaka T, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Efficacy of reduction therapy of natural human β -interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load	Hepatol Res	42	949-957	2012

Akuta N, <u>Suzuki F</u> , Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Association of IL28B Genotype and Viral Response of Hepatitis C Virus Genotype 2 to Interferon Plus Ribavirin Combination Therapy	J Med Virol	84	1593-1599	2012
Takeyasu M, Akuta N, <u>Suzuki F</u> , Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma	J Med Virol	84	1199-1207	2012
Akuta N, <u>Suzuki F</u> , Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1	J Med Virol	84	1097-1105	2012
Matsumoto N, Arase Y, Seko Y, Imai N, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Kobayashi M, Suzuki Y, Saitoh S, <u>Suzuki F</u> , Ikeda K, Kumada H, Aida K, Kobayashi T.	Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of < 126 mg/dl	Hepatol Res	42	558-563	2012
Imai N, Ikeda K, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, <u>Suzuki F</u> , Suzuki Y, Arase Y, Kumada H.	Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma	Japanese Journal of Clinic	42	175-182	2012
Arase Y, Kobayashi M, <u>Suzuki F</u> , Suzuki Y, Kawamura Y, Akuta N, Imai N, Kobayashi M, Sezaki H, Matsumoto N, Saitoh S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Hsieh SD, Ogawa K, Tanabe M, Tsuji H, Kobayashi T.	Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients	Hepatol Res	42	264-272	2012

Karino Y, Toyota J, Ikeda K, <u>Suzuki F</u> , Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Dennis Hernandez, Fei Yu, Fiona McPhee, Kumada H.	Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir	J Hepatol	2012.11.012	In press	2012
Suzuki Y, Ikeda K, <u>Suzuki F</u> , Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Wenhua Hu, Timothy Eley, Fiona McPhee, Eric Hughes, Kumada H.	Dual Oral Therapy with Daclatasvir and Asunaprevir for Patients with HCV Genotype 1b Infection and Limited Treatment Options	J Hepatol	2012.09.037	In press	2012
Hosaka T, <u>Suzuki F</u> , Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection	Hepatology	10.1002	In press	2012
<u>Suzuki F</u> , Suzuki Y, Sezaki H, Akuta N, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Mineta R, Watahiki S, Kobayashi M, Nakayasu Y, Tsuda H, Aoki K, Yamada I, Kumada H.	Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients	Hepatol Res	10.1111	In press	2012
Tadokoro K, Kobayashi M, <u>Suzuki F</u> , Tanaka C, Yamaguchi T, Nagano M, Kumada H.	Comparative quantitative analysis of hepatitis C mutation at amino acids 70 and 91 in the core region by the Q-invader assay	J Virol Methods	10.1016/2012.10.011	In press	2012
Hosaka T, <u>Suzuki F</u> , Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study	J Gastroenterol	10.1007/0535-012-0688-7	In press	2012

Yamada I, <u>Suzuki F</u> , Kamiya N, Aoki K, Sakurai Y, Kanou M, Matsui H, Kumada H.	Safety, pharmacokinetics, and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection	J Viral Hepat	19	112-119	2012
Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, Kobayashi M, Sezaki H, Saitoh S, Hosaka T, Ikeda K, <u>Kumada H</u> , Kobayashi T.	Effect of type 2 diabetes on risk for malignancies included hepatocellular carcinoma in chronic hepatitis C	Hepatology	10.1002/26087	In press	2012
Seko Y, Ikeda K, Kawamura Y, Fukushima T, Hara T, Sezaki H, Hosaka T, Akuta N, <u>Suzuki F</u> , Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Kumada H.	Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma	Hepatol Res	10.1111/12041	In press	2013
今井則博、池田健次、瀬古裕也、原祐、大野敦司、松本直樹、川村祐介、保坂哲也、小林正宏、斎藤聡、瀬崎ひとみ、芥田憲夫、鈴木文孝、鈴木義之、荒瀬康司、熊田博光	ミリプラチン動注化学療法を併用したラジオ波凝固療法	肝臓	53(6)	351-354	2012
朝比奈靖浩、泉並木、桶谷眞、熊田博光、小池和彦、 <u>鈴木文孝</u> 、滝川一、田中篤、坪内博仁、林紀夫、平松直樹、四柳宏	C型肝炎治療ガイドライン(第1版) 日本肝臓学会肝炎診療ガイドライン作成委員会	肝臓	53(6)	355-395	2012
原祐、芥田憲夫、福島泰斗、瀬古裕也、川村祐介、瀬崎ひとみ、保坂哲也、小林正宏、斎藤聡、鈴木義之、 <u>鈴木文孝</u> 、荒瀬康司、池田健次、小林万利子、熊田博光	高齢者C型慢性肝炎に対するテラプレビル1500mg減量投与のパイロット・スタディ	肝臓	53(10)	624-626	2012

<p>小関至、狩野吉康、 豊田成司、高橋祥一、 川上由育、茶山一彰、 芥田憲夫、鈴木文孝、 熊田博光</p>	<p>PEG-IFN/Ribavirin/Telaprevir 三剤併用療法における 薬剤投与率の抗ウイルス効果に およぼす影響</p>	<p>肝臓</p>	<p>53(2)</p>	<p>69-77</p>	<p>2012</p>
--	--	-----------	--------------	--------------	-------------

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
	Q5. HBc抗体・HBs抗体のみが陽性の患者はどのような点に注意して診療すべきか？	泉並木 黒崎雅之	すべての内科医に役立つ肝疾患—なるほどQ&A	羊土社	東京	2011年	24-27
	Q13. B型肝炎の症例にも、インターフェロンや核酸アナログの治療適応はあるか？	泉並木 黒崎雅之	すべての内科医に役立つ肝疾患—なるほどQ&A	羊土社	東京	2011年	51-53

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kiyohashi K, <u>Nakagawa M</u> et al.	Wnt5a Signaling Mediates Biliary Differentiation of Fetal Hepatic Stem/Progenitor Cells.	<i>Hepatology</i>	In press		2013
Nitta S, <u>Nakagawa M</u> , et al.	Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type-I interferon-dependent innate immunity.	<i>Hepatology</i>	57	46-58	2013
<u>Nakagawa M</u> , et al.	Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C	<i>Hepatol Int</i>	Epub		2013
Kurosaki M <u>Nakagawa M</u> , et al.	Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C.	<i>J Hepatol</i>	56	602-608	2012
Kusano-Kitazume A, <u>Nakagawa M</u> , et al.	Identification of Novel N-(Morpholine-4-Carbon yloxy) Amidine Compounds as Potent Inhibitors against Hepatitis C Virus Replication.	<i>Antimicrob Agent Chemother</i>	56	1315-23	2012